Appendix 4D
only | 1. | Company Details | ||||||||||
Name of Entity | ||||||||||||
Zelira Therapeutics Limited | ||||||||||||
ABN | Half year ended ("current period") | Half year ended ("previous period") | ||||||||||
use | 27 103 782 378 | 31 December 2021 | 31 December 2020 | |||||||||
2. | Results for announcement to the market | |||||||||||
AUD $ | ||||||||||||
2.1 Revenues from ordinary activities | Up | 700% to | 727,699 | |||||||||
personal | 2.2 Profit / (loss) from ordinary activities after tax | |||||||||||
attributable to members - 31 December 2020: loss of | Down | 56% to | (5,613,420) | |||||||||
($3,594,626) | ||||||||||||
2.3 Net profit / (loss) for the period attributable to | Down | 56% to | (5,613,420) | |||||||||
members - 31 December 2020: loss of ($3,594,626) | ||||||||||||
2.4 Dividends | Amount per security | Franked amount per security | ||||||||||
Interim dividend declared | N/A | N/A | ||||||||||
2.5 Record date for determining entitlements to the dividend | N/A | |||||||||||
2.6 Brief explanation of any of the figures in 2.1 to 2.4 above necessary to enable figures to be | ||||||||||||
understood | ||||||||||||
Commercialisation continued to ramp up during the period with sales momentum gaining for current | ||||||||||||
products in market and new products being clinically tested and launched. Distribution agreements | ||||||||||||
For | were entered into in both German and New Zealand and the Company successfully supported Levin | |||||||||||
Health's receipt of ethics approval for Phase 2A clinical trial for chronic pain. | ||||||||||||
3. Net tangible assets per security | 31 December 2021 | 31 December 2020 | ||||||||||
Net tangible asset backing per ordinary security | 0.006 | 0.008 | ||||||||||
4. | Details of entities over which control has been gained or lost | |||||||||||
4.1. Control gained over entities | ||||||||||||
N/A | ||||||||||||
use only
4.2. Control lost over entities | |||||||
N/A | |||||||
5. | Dividends | ||||||
Individual dividends per security | |||||||
Franked | Amount per | ||||||
Amount | security of | ||||||
Date dividend is | amount per | ||||||
per | foreign | ||||||
payable | security at | ||||||
security | source | ||||||
30% tax | |||||||
dividend | |||||||
Interim dividend: | |||||||
Current year | N/A | N/A | N/A | N/A | |||
Previous year | N/A | N/A | N/A | N/A | |||
6. | Dividend reinvestment plans | ||||||
The dividend or distribution plans shown below are in operation.
N/A
The last date(s) for receipt of election notices for
the dividend or distribution plans.
N/A
For personal
7. Details of associates and joint entities
N/A
8. Foreign entities
N/A
9. If the accounts are subject to audit dispute or qualification, details are described below.
N/A
Sign here: | Date: | 23 February 2022 |
Managing Director | |
Print Name: | Oludare Odumosu |
For personal use only
2021
HALF-YEAR FINANCIAL REPORT
31 DECEMBER 2021
Zelira Therapeutics Ltd
ABN 27 103 782 378
For personal use only
Zelira Therapeutics Ltd Half-Year Financial Report 31 December 2021 | 2 |
For personal use only
Contents
4 | Directors' Report |
8 | Auditor's Independence |
Declaration |
Condensed Consolidated
9 Statement of
Comprehensive Income
10 | Condensed Consolidated |
Statement of Financial Position |
11 | Condensed Consolidated |
Statement of Changes in Equity |
12
13
24
25
27
Condensed Consolidated
Statement of Cash Flows
Notes to the Condensed Consolidated Financial Statements
Directors' Declaration
Independent Auditor's
Review Report
Corporate Directory
All announcements and financial reports are available on our website www.zeliratx.com
3
Zelira Therapeutics Ltd Half-Year Financial Report 31 December 2021
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Zelda Therapeutics Ltd. published this content on 23 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 February 2022 05:48:04 UTC.